Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parasite clearance comparison of dihydroartemisinin-piperaquine and artemether-lumefantrine in under-five children with uncomplicated malaria
PACTR202007553348930Not yet recruiting
- Sponsor
- Ahmed Abdulakeem
- Start
- Sep 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of dihydroartemisinin, piperaquine, artemether and lumefantrine in malaria and Falciparum malaria (PF), sponsored by Ahmed Abdulakeem. Primary endpoints: Adequate clinical and parasitological response, Early treatment failure and 2 more. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
dihydroartemisininpiperaquineartemetherlumefantrine
03
Conditions
malariaFalciparum malaria (PF)
Beyond the preview
Go deeper on PACTR202007553348930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202007553348930.